Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China
- PMID: 33532504
- PMCID: PMC7834780
- DOI: 10.1155/2021/1349042
Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China
Abstract
Objective: To identify the clinical characteristics, magnetic resonance imaging (MRI) results, and prognostic factors of neuropsychiatric (NP) systemic lupus erythematosus (SLE; NPSLE) in a relatively large patient series in China.
Methods: Data of patients with NPSLE at Peking Union Medical College Hospital (PUMCH) were collected retrospectively from June 2012 to June 2016. NPSLE patients were compared with 220 non-NPSLE patients. Survival rates were evaluated using the Kaplan-Meier curves, log-rank test, and Cox proportional hazards modeling. Cranial MRI results were also studied.
Results: Of the 194 included patients, sixteen subtypes of NPSLE were identified, and the most common manifestations were seizure (36.6%), acute confusional state (25.3%), and cerebral vascular disease (15.5%). Compared with the non-NPSLE group, NPSLE patients were significantly more likely to have typical lupus symptoms, higher Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores (P = 0.002), and positive rate of anti-ribosomal P protein antibodies (P = 0.008). Patients with seizure were more likely to have higher SLEDAI-2K scores and positive anti-β2GP1 than non-NPSLE patients. Sixteen patients died during follow-up. The most common cause of death was infection (37.5%). NPSLE significantly decreased survival rates of SLE patients. Patients with elevated serum creatinine (P = 0.001), hypocomplementemia (P = 0.031), and SLEDAI - 2K scores ≥ 15 (P = 0.014) had shorter survival periods. Eighty-two patients underwent detailed cranial MRI analysis; of these, 50 (61.0%) had abnormal results. Small vessel disease was the most common abnormal finding, followed by inflammatory-like lesions and large vessel disease.
Conclusions: High disease activity and positive rate of anti-ribosomal P protein antibodies may be risk factors for NPSLE. NPSLE decreases survival rates of SLE patients. Renal insufficiency and high disease activity are predictive of poor prognoses for NPSLE patients.
Copyright © 2021 Shangzhu Zhang et al.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures
Similar articles
-
Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study.Mod Rheumatol. 2020 Mar;30(2):321-326. doi: 10.1080/14397595.2019.1589912. Epub 2019 Apr 8. Mod Rheumatol. 2020. PMID: 30836042
-
Differences between central nervous system infection and neuropsychiatric systemic lupus erythematosus in patients with systemic lupus erythematosus.J Int Med Res. 2018 Jan;46(1):485-491. doi: 10.1177/0300060517722695. Epub 2017 Aug 21. J Int Med Res. 2018. PMID: 28823196 Free PMC article.
-
Clinical features of central nervous system infections and experience in differential diagnosis from neuropsychiatric lupus erythematosus in a cohort of 8491 patients with systemic lupus erythematosus.Arthritis Res Ther. 2019 Aug 19;21(1):189. doi: 10.1186/s13075-019-1971-2. Arthritis Res Ther. 2019. PMID: 31426834 Free PMC article.
-
A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus.Autoimmun Rev. 2016 Feb;15(2):124-38. doi: 10.1016/j.autrev.2015.10.003. Epub 2015 Oct 23. Autoimmun Rev. 2016. PMID: 26497108 Review.
-
Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study.Lupus. 2006;15(10):651-7. doi: 10.1177/0961203306070990. Lupus. 2006. PMID: 17120591 Review.
Cited by
-
Prediction model for developing neuropsychiatric systemic lupus erythematosus in lupus patients.Clin Rheumatol. 2024 Jun;43(6):1881-1896. doi: 10.1007/s10067-024-06970-z. Epub 2024 Apr 27. Clin Rheumatol. 2024. PMID: 38676758
-
Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis.Front Pharmacol. 2023 Aug 4;14:1207385. doi: 10.3389/fphar.2023.1207385. eCollection 2023. Front Pharmacol. 2023. PMID: 37601046 Free PMC article.
-
Neuropsychiatric systemic lupus erythematosus events: An Asian African cosmopolitan study in a tertiary care university hospital.Medicine (Baltimore). 2025 Aug 1;104(31):e43617. doi: 10.1097/MD.0000000000043617. Medicine (Baltimore). 2025. PMID: 40760612 Free PMC article.
-
Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade.Brain Sci. 2022 Jan 30;12(2):192. doi: 10.3390/brainsci12020192. Brain Sci. 2022. PMID: 35203955 Free PMC article. Review.
-
Biomarkers for systemic lupus erythematosus: A scoping review.Immun Inflamm Dis. 2024 Oct;12(10):e70022. doi: 10.1002/iid3.70022. Immun Inflamm Dis. 2024. PMID: 39364719 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
